• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter by Löwe et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up".

作者信息

Löwe Axel Lennart, Collet Tinh-Hai, Rodondi Nicolas

机构信息

Institute of Primary Health Care (Berner Institut für Hausarztmedizin), University of Bern, Switzerland (A.L.L., N.R.).

Department of General Internal Medicine, Inselspital, Bern University Hospital, Switzerland (A.L.L., N.R.).

出版信息

Circulation. 2018 May 29;137(22):2415-2416. doi: 10.1161/CIRCULATIONAHA.117.032213.

DOI:10.1161/CIRCULATIONAHA.117.032213
PMID:29844076
Abstract
摘要

相似文献

1
Letter by Löwe et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up".洛维等人就文章《低密度脂蛋白胆固醇水平原发性升高至190mg/dL及以上男性心血管疾病一级预防中的低密度脂蛋白胆固醇降低：西苏格兰冠心病预防研究（WOSCOPS）5年随机试验及20年观察性随访分析》所写的信
Circulation. 2018 May 29;137(22):2415-2416. doi: 10.1161/CIRCULATIONAHA.117.032213.
2
Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.男性原发性低密度脂蛋白胆固醇水平升高至 190mg/dL 或以上的心血管疾病一级预防中降低低密度脂蛋白胆固醇：来自 WOSCOPS（苏格兰西部冠状动脉预防研究）5 年随机试验和 20 年观察随访的分析。
Circulation. 2017 Nov 14;136(20):1878-1891. doi: 10.1161/CIRCULATIONAHA.117.027966. Epub 2017 Sep 6.
3
Letter by Koh Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up".Koh 就文章《低密度脂蛋白胆固醇水平原发性升高至190mg/dL及以上男性心血管疾病一级预防的低密度脂蛋白胆固醇降低：来自WOSCOPS（苏格兰西部冠心病预防研究）5年随机试验和20年观察性随访的分析》所写的信
Circulation. 2018 May 29;137(22):2417-2418. doi: 10.1161/CIRCULATIONAHA.117.033136.
4
Response by Vallejo-Vaz et al to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up".瓦列霍 - 瓦斯等人对关于文章《低密度脂蛋白胆固醇水平原发性升高至190mg/dL及以上男性心血管疾病一级预防的低密度脂蛋白胆固醇降低治疗：西苏格兰冠心病预防研究（WOSCOPS）5年随机试验及20年观察性随访分析》的信件的回应
Circulation. 2018 May 29;137(22):2419-2420. doi: 10.1161/CIRCULATIONAHA.118.033781.
5
Closing the Remaining Evidence Gap: Randomized Controlled Trial Data to Support Statin Therapy for Low-Density Lipoprotein ≥190 mg/dL.弥合剩余的证据差距：支持他汀类药物治疗低密度脂蛋白≥190 mg/dL的随机对照试验数据
Circulation. 2017 Nov 14;136(20):1892-1894. doi: 10.1161/CIRCULATIONAHA.117.030989.
6
[Statins in primary prevention of coronary heart disease].[他汀类药物在冠心病一级预防中的应用]
Wien Med Wochenschr. 1999;149(5-6):129-38.
7
West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.苏格兰西部冠心病预防研究：高危人群的识别及与其他心血管干预试验的比较。
Lancet. 1996 Nov 16;348(9038):1339-42.
8
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.米泊美生，一种载脂蛋白 B 合成抑制剂，可降低高心血管风险严重高胆固醇血症患者的致动脉粥样硬化脂蛋白：一项随机、双盲、安慰剂对照试验。
J Am Coll Cardiol. 2013 Dec 10;62(23):2178-84. doi: 10.1016/j.jacc.2013.07.081. Epub 2013 Sep 4.
9
Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.他汀类药物一级预防心血管疾病的证据：更新的临床结果与实际实践之间的差距。
Arch Cardiovasc Dis. 2014 Mar;107(3):188-200. doi: 10.1016/j.acvd.2014.01.011. Epub 2014 Mar 7.
10
Individualized Risk Communication and Outreach for Primary Cardiovascular Disease Prevention in Community Health Centers: Randomized Trial.社区卫生中心原发性心血管疾病预防的个性化风险沟通与推广：随机试验
Circ Cardiovasc Qual Outcomes. 2015 Nov;8(6):560-6. doi: 10.1161/CIRCOUTCOMES.115.001723. Epub 2015 Nov 10.